Improved Immune Response in Blood Cancer Patients After Third COVID-19 Vaccination

Strategic Insights -

Research has shown that weakened immune systems of blood cancer patients can improve after receiving a third COVID-19 vaccination. Patients with lymphoma have been found to have defects in their immunity system, limiting its response to vaccination. However, a recent study discovered improvements in antibody and T-Cell responses after a third vaccine dose, except in patients who had recently received a certain antibody treatment for their cancer. This study provides crucial insights into the effectiveness of vaccination in immunosuppressed patients and highlights the importance of continued research in this area.

Key Takeaways:

  • The study collected blood samples from 457 adult lymphoma patients before and after vaccination to evaluate the strength of the immune system's response to the vaccines.
  • Only around 50% of patients undergoing active cancer treatment had no detectable antibody levels after the second vaccination, but T cell responses could be detected in about 67% of all patients.
  • After a third dose, 92% of patients who were not undergoing anti-CD20 treatment for their cancer showed improved antibody responses, compared to 17% who were receiving that treatment.
  • The study measured the ability of antibodies in the blood samples to prevent the viral spike protein from binding to ACE2 proteins and found a good link between the level of antibodies in the blood samples and how well these antibodies blocked the virus from binding to the ACE2 protein.
  • The research team plans to follow up this study with further analysis into the clinical outcomes of patients who were infected with COVID-19.

Statistics:

  • 457 adult lymphoma patients participated in the study.
  • 50% of patients undergoing active cancer treatment had no detectable antibody levels after the second vaccination.
  • 67% of all patients had detectable T cell responses.
  • 92% of patients who were not undergoing anti-CD20 treatment for their cancer showed improved antibody responses after a third dose.
  • 17% of patients receiving anti-CD20 treatment for their cancer showed improved antibody responses after a third dose.

Sources:

  • "New research has found that the weakened immune systems of blood cancer patients can improve after they receive a third COVID-19 vaccination." (NewsRx)
  • "The study was funded by the Blood Cancer UK Vaccine Research Collaborative and has been published in the journal Nature Cancer." (NewsRx)
  • "Dr Sean Lim, Associate Professor and Honorary Consultant in Haematological Oncology at the University of Southampton, who led the research." (NewsRx)
  • "The study aimed to evaluate the strength of the immune system's response to the vaccines and to help predict how effective the vaccine could be for lymphoma patients." (NewsRx)
  • "The scientists measured the ability of antibodies in the blood samples to prevent the viral spike protein from binding to ACE2 proteins." (NewsRx)